Cuba strengthens biotech industry through Eurasian partnerships

Home/Pharma News | Posted 14/07/2023 post-comment0 Post your comment

Cuba is consolidating its position in the field of biotechnology thanks to cooperation with several Eurasian nations, in particular Russia and Belarus.

138 AA011155

Recently, three key agreements were signed in Sochi, Russia, in which the three countries will boost the development of medical devices, technology transfer and assimilation, and scientific-technical exchange. This means that there will be closer collaboration in these areas, benefiting all parties involved. 

The first agreement is the creation of a memorandum of understanding that will allow the establishment of a strategy for scientific and technical cooperation, the transfer and assimilation of technology, as well as the commercialization of active ingredients for the production of medicines and their reference patterns.

The second is a pharmaceutical supply contract, that is, the acquisition of various active ingredients of generic drugs; for example, the antibiotic Azithromycin.

The third one is a letter of intent from the Eurasian Economic Union to create a multinational alliance that will enable the achievement of an increased capacity in the short term, in pursuit of the development and production of vaccines and medicines.

According to the President of the Business Group of Biotechnological and Pharmaceutical Industries (BioCubaFarma), Eduardo Martínez Díaz, ‘we propose a portfolio of products in programs for the treatment of infectious and chronic diseases such as oncology, neurology and diabetes, which can be marketed in this Eurasian zone, but also in the Latin American region. In addition, technology transfers between our countries can be included, contributing to increase their capacity in the manufacturing of medicines, vaccines, medical devices, and equipment. Another important point is to promote scientific, academic, and business exchanges for the development of new products’.

This alliance will provide very positive results for both the Russian Federation and Cuba, as well as for other countries in the Eurasian and Latin American and Caribbean regions.

Already in September 2022, the United Nations Development Program (UNDP) announced the implementation of a loan of €46.7 million (US$45.25 million) to support Cuba's bio-pharmaceutical industry and improve the national response capacity to diseases such as COVID-19 [1].

Related articles
AMLAC: regulatory agency for medicines in Latin America and the Caribbean established

Biosimilars approved in Cuba

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Actualización de la declaración de posición de GADECCU sobre los biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Actualización de la declaración de posición de GADECCU sobre los biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. New funding to strengthen Cuba's biopharmaceutical industry []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jul 14]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.


comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010